08:00 , Feb 22, 2016 |  BioCentury  |  Finance

Reinventing BioInvent

A proposed financing by BioInvent International AB (SSE:BINV) would give the cancer antibody company new life to reach clinical proof of concept for three assets and fund preclinical immuno-oncology programs that it had been forced...
07:00 , Apr 20, 2015 |  BC Week In Review  |  Clinical News

BioInvent International A preclinical data

In mice, BI-1206 prevented tumor cell internalization of Rituxan rituximab, a chimeric mAb against CD20 antigen, and subsequently increased cell surface accessibility and immune effector cell-mediated antitumor activity. Data were published in Cancer Cell. This...